1-4 of 4
Michael Yellin, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers

Niroshana Anandasabapathy, MD, PhD, Arlene Hurley, ANP, CCRC, Marina Caskey, Christine Trumpfheller, Popi Sarma, James Pring, Maggie Pack, Renee Riggs, Jennifer Green, Michael Yellin, MD, Thomas A. Davis, MD, Tibor Keler, PhD, Sarah Schlesinger, MD
Journal: Blood
Blood (2012) 120 (21): 4124.
https://doi.org/10.1182/blood.V120.21.4124.4124
Published: 2012
Journal Articles

Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms

Li-Zhen He, MD, Larry Thomas, PhD, Jeffery Weidlick, Laura Vitale, Tom O'Neill, Naseem Prostak, Karuna Sundarapandiyan, Henry Marsh, PhD, Michael Yellin, MD, Thomas A. Davis, MD, Tibor Keler, PhD
Journal: Blood
Blood (2011) 118 (21): 2861.
https://doi.org/10.1182/blood.V118.21.2861.2861
Published: 2011
Journal Articles

Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.

Stephen M. Ansell, MD, PhD, John C. Byrd, MD, Steven M. Horwitz, MD, Peter Borchmann, MD, Andreas Engert, MD, Roger Strair, MD, Khuda D. Khan, MD, Steven A. Fischkoff, MD, Michael Yellin, MD
Journal: Blood
Blood (2004) 104 (11): 2636.
https://doi.org/10.1182/blood.V104.11.2636.2636
Published: 2004
Journal Articles

The Human Anti-CD30 Antibody 5F11 Activates NF-kB and Sensitizes Lymphoma Cells to Bortezomib Induced Apoptosis.

Elke Pogge, PhD, Boris Boell, MS, Samir Tawadros, MS, Katrin Reiners, PhD, Peter Borchmann, MD, Hinrich Hansen, PhD, Robert Graziano, PhD, Michael Yellin, MD, Andreas Engert, MD
Journal: Blood
Blood (2004) 104 (11): 3295.
https://doi.org/10.1182/blood.V104.11.3295.3295
Published: 2004